Biotech Values

[DewDiligence]

Re: GTCB / tidbit from CC on sepsis

Overall, the CC was a non-event, but there was a tidbit pertaining to the use of ATryn in sepsis.

In the “simulated sepsis” trial at the Medical University of Vienna (#msg-7268415), the investigators selected ATryn instead of plasma-derived AT because they believed that ATryn is purer. Specifically, the investigators wanted ATryn because they think it contains less heparin contamination than plasma-derived AT.

Whether this is a matter of clinical significance remains to be seen, but there is some evidence that heparin may counteract the benefit of AT therapy in sepsis: e.g. #msg-7007573 (see Conclusions paragraph about 2/3 of the way down) and #msg-7007635.